ESR2 and breast carcinoma: It is known to fail for treating breast cancer due to (i) the existence of ERβ (ii) an imbalance between estrogen biosynthesis and catabolism (iii) an altered bioavailability iv) altered cellular trafficking of ER (v) nongenomic effects of ER (vi) transcriptional dysregulation of ER target genes [58].